The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome

References

• Asuncion M, Calvo, RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434–2438.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Christakou C. Prevalence, definition and clinical manifestations of polycystic ovary syndrome. Endocrinol Nutr 2006;53 (Suppl 1):25–33.
   Google Scholar
• Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237–4245.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005;26: 251–282.
   PubMed Web of Science ®Google Scholar
• Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS, Strauss JF, 3rd, McAllister JM. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:5925–5933.
   PubMed Web of Science ®Google Scholar
• Gambineri A, Pasquali R. Insulin resistance, obesity and metabolic syndrome in polycystic ovary syndrome. Endocrinol Nutr 2006;53 (Suppl 1):49–55.
   Google Scholar
• Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006;166:2081–2086.
   PubMedGoogle Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800.
   PubMed Web of Science ®Google Scholar
• Utiger RD. Insulin and the polycystic ovary syndrome. N Engl J Med 1996;335:657–658.
   PubMed Web of Science ®Google Scholar
• Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77:1095–1105.
   PubMed Web of Science ®Google Scholar
• Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929–1935.
   PubMed Web of Science ®Google Scholar
• Cattrall FR, Healy DL. Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:803–812.
   PubMed Web of Science ®Google Scholar
• Dejager S, Pichard C, Giral P, Bruckert E, Federspield MC, Beucler I, Turpin G. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf) 2001;54:455–462.
   PubMedGoogle Scholar
• Castelo-Branco C, Steinvarcel F, Osorio A, Ros C, Balasch J. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism. Gynecol Endocrinol 26:736–742.
   PubMedGoogle Scholar
• Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810–1812.
   PubMed Web of Science ®Google Scholar
• Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th edPhiladelphia: Lippincott Williams & Wilkins2005.
   Google Scholar
• Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs 2004;64:2447–2462.
   PubMed Web of Science ®Google Scholar
• Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003;361:1894–1901.
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003;46:325–340.
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Nestler JE, Ostlund RE, Apridonidze T, Diamanti-Kandarakis E. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod 2008;23:1439–1446.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139–144.
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Diamanti-Kandarakis E, Jr., Ostlund RE, Jr., Apridonidze T, Iuorno MJ, Nestler JE. Altered d-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29:300–305.
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8:417–423.
   PubMedGoogle Scholar
• Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 α activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075–4079.
   PubMed Web of Science ®Google Scholar
• Minozzi M, D'Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online 2008;17:579–582.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314–1320.
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007;23:700–703.
   PubMed Web of Science ®Google Scholar
• Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009;13:105–110.
   PubMed Web of Science ®Google Scholar
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003;88:1927–1932.
   PubMed Web of Science ®Google Scholar
• Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007;30:471–478.
   PubMed Web of Science ®Google Scholar
• Frempong BA, Ricks M, Sen S, Sumner AE. Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. J Clin Endocrinol Metab 2008;93:2097–2103.
   PubMed Web of Science ®Google Scholar
• van Rooijen M, von Schoultz B, Silveira A, Hamsten A, Bremme K. Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. Am J Obstet Gynecol 2002;186:44–48.
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 2002;77:919–927.
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–1447.
   PubMed Web of Science ®Google Scholar
• Zacche MM, Caputo L, Filippis S, Zacche G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:508–513.
   PubMed Web of Science ®Google Scholar
• Rajkhowa M, Neary RH, Kumpatla P, Game FL, Jones PW, Obhrai MS, Clayton RN. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:3389–3394.
   PubMed Web of Science ®Google Scholar
• Berneis K, Rizzo M, Lazzarini V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:186–189.
   PubMed Web of Science ®Google Scholar
• Tornvall P, Karpe F, Proudler A, Bavenholm P, Landou C, Olivecrona T, Hamsten A. High-density lipoprotein: relations to metabolic parameters and severity of coronary artery disease. Metabolism 1996;45:1375–1382.
   PubMedGoogle Scholar